Open Access Open Access  Restricted Access Access granted  Restricted Access Subscription or Fee Access

Vol 13, No 3 (2016)


Transepithelial initiation of allergic response

Gushchin I.S.


The paper is focused on structure and functions of airway epithelial barrier and allergen-mediated innate immune response of the epithelium leading to facilitation of allergy development.
Russian Journal of Allergy. 2016;13(3):3-10
pages 3-10 views

Is the level of cord blood IgE considered to be a marker of antenatal «programming» of allergic phenotype in newborn infant?

Evsyukova I.I., Ilchukova O.V.


The article presents the literature data and the results of own research on the allergic phenotype diagnostics and the prediction capability of IgE level in the cord blood in newborns.
Russian Journal of Allergy. 2016;13(3):11-14
pages 11-14 views

Agreed recommendations on the use of FDC budesonide/formoterol in a single inhaler (SMART) for the treatment of patients with bronchial asthma

- -.


Conclusion paragraphs were discussed at the Advisory Board and adopted by majority of votes during voting. After Advisory Board the initiative group edited the draft opinion in accordance with the received comments and suggestions. The final draft of conclusion has been agreed by all experts of the Advisory Board.
Russian Journal of Allergy. 2016;13(3):15-29
pages 15-29 views

Influence of secondary immune deficiency syndrome on the course of atopic dermatitis in children

Sizyakina L.P., Penechko E.M., Didenko I.V.


Allergological and immunological parameters in children with atopic dermatitis complicated by secondary immune deficiency syndrome are presented. It was found that concomitant secondary immune deficiency syndrome, which manifested by frequent acute respiratory viral infections, significantly weigh down the clinical features of atopic dermatitis in children.
Russian Journal of Allergy. 2016;13(3):30-34
pages 30-34 views

Сoncomitant conditions in children’s clinical allergist practice. Difficult patients

Revyakina V.A., Shekhetov A.A., Kiseleva M.A., Larkova I.A., Kuvshinova E.D., Shavkina M.I., Mukhortykh V.A.


The article presents the clinical case of epidermolysis bullosa and atopic dermatitis in child. Such patients require in-patient treatment due to severe progressive course of the disease and the ineffectiveness of therapy.
Russian Journal of Allergy. 2016;13(3):35-40
pages 35-40 views

Clinical efficacy of allergen-specific immunotherapy in children with combined forms of respiratory trees pollen allergy

Emelina Y.N., Tuzankina i.A., Zurochka A.V.


Background. To evaluate the effectiveness of three courses of allergenspecific immunotherapy (ASIT) in children with combined forms of respiratory pollen allergy. Materials and methods. We observed 69 children aged 10,6±0,4 with combined forms of hay fever. All children were randomized and divided into 3 subgroups who received allergen-specific immunotherapy (ASIT) with Fostal, Staloral and water-salted mixed extracts of trees pollen. The comparison group consisted of 16 children with combined forms of hay fever without ASIT. The effectiveness of treatment was assessed by dynamics of the allergic rhino-conjunctivitis symptoms using a visual analogue scale and dynamics of the level of control over the symptoms of bronchial asthma using standardized questionnaires - the Asthma Control Test. Results. The first course of allergen-specific immunotherapy reduced the severity of rhinorrhea by 48%, nasal congestion - by 45,1%, itching eyes - by 40,8%, nasal itching - by 30,6%, complete control of asthma symptoms was achieved in 61,2%; ASIT reduced the likelihood of an uncontrolled flow of asthma in 17,6 times compared with children who did not receive immunotherapy. After three courses of allergen-specific immunotherapy with pollen allergens a decrease of the severity of allergic rhino-conjunctivitis symptoms and increase of the level of asthma symptoms control in all subgroups was shown.
Russian Journal of Allergy. 2016;13(3):41-48
pages 41-48 views

Levocetirizine in clinical practice of allergist

Elisyutina O.G., Shtyrbul O.V.


Levocetirizine is an effective H1-blocker of histamine receptors in complex treatment of various allergic diseases. The article presents the literature data and own observational data on clinical efficacy and safety of levocetirizine in the treatment of allergic diseases such as allergic rhinitis, bronchial asthma, allergic dermatoses.
Russian Journal of Allergy. 2016;13(3):49-50
pages 49-50 views

The correction of epidermal barrier dysfunction in atopic dermatitis patients

Elisyutina O.G., Shtyrbul O.V., Zemskaya E.N.


Atopic dermatitis is chronic inflammatory multifactorial disease, which has genetic disorders, immune mechanisms of development and is under the ainfluence of a combination of exogenous and endogenous factors. Recently a leading role of the epidermal barrier dysfunction in the pathogenesis of atopic dermatitis was shown. The article presents data about emollient for skin care efficacy - Cetaphil® RESTORADERM, which consists of preceramides and filaggrin breakdown products in complex treatment of atopic dermatitis patients.
Russian Journal of Allergy. 2016;13(3):59-64
pages 59-64 views

Therapeutic comparability of Dezrinit and Nazonex® in control of symptoms of allergic rhinitis. The results of a multicenter, open, randomized, comparative study in parallel groups

Ilina N.I., Fedoskova T.G., Astafieva N.G., Gorychkina L.A., Edin A.S., Lopatin A.S., Ukhanova O.P., Khanova F.M., Khanferyan R.A.


Background. To study efficacy and safety of Dezrinit (mometasone furoate, metered dose nasal spray, 200 pg/day) in comparison with Nasonex® (mometasone furoate, metered dose nasal spray, 200 pg/day) upon administration for 14 days in adult patients with seasonal allergic rhinitis. Materials and methods. A total of 141 patients were enrolled into the study at 8 study centers in the RF, of which 134 patients were randomized: 67 patients into the experimental group (Dezrinit) and 67 patients into the comparison group (Nasonex®). patients were randomized to receive treatment either with Dezrinit or Nasonex®. Efficacy was assessed based on reflective Total Nasal Symptom Score (rTNSS) and instantaneous Total Nasal Symptom Score (iTNSS); reflective Total Ocular Symptom Score (rTOSS) and instantaneous Total Ocular Symptom Score (iTOSS). Overall proportion of patients who responded to treatment was evaluated according to overall assessment of treatment efficacy both by a patient and by an investigator. AEs were reported for safety assessment. Results. After 14 days of treatment a marked improvement of symptoms was observed in both groups based on all assessed scores. Mean change (SD) in rTNSS from baseline was -11,91 (4,625) scores and -11,64 (4,58) scores in the experimental and comparison groups, respectively (within group differences, p<0,001). Mean difference (SD) in rTNSS from baseline between experimental and comparison groups was -0,2 (0,519) scores [95% confidence interval (CI) -1,231; 0,825]. Analysis of primary efficacy endpoint demonstrated similar results in pp population. Mean change (SD) in iTNSs, rTOSS and iTOSS from baseline was -5,97 (2,569) and -5,93 (2,809) scores; -6,41 (4,801) and -5,09 (4,505) scores; -3,38 (2,4) and -2,54 (2,47) scores in the experimental and comparison groups, respectively (within group differences for all comparisons, p<0,001). Treatment efficacy as assessed by patients and investigators, was evaluated as complete response and significant relief in both treatment groups: 75 and 73,2% investigators in the experimental and comparison groups; 75 and 76,2% patients in the experimental and comparison groups, respectively. No serious adverse events were reported. Conclusion. Available data confirm efficacy comparability and safety of Dezrinit, when compared to Nasonex®, which suggests a possibility of safe replacement of the original drug by the generic product without loss of treatment efficacy.
Russian Journal of Allergy. 2016;13(3):65-74
pages 65-74 views

Efficacy and safety of desloratadine in chronic urticaria therapy

Fedenko E.S., Erina O.A., Dzigoeva A.A.


This review is devoted to analyses of data on efficacy and safety of desloratadine in chronic urticaria therapy.
Russian Journal of Allergy. 2016;13(3):75-78
pages 75-78 views

Aeropalinological feature of the seaside resorts of the crimea and modern opportunities of elimination therapy

Belyaeva S.N., Kovtunenko I.N., Govorun M.I., Pirogova M.E., Dudchenko L.C.
Russian Journal of Allergy. 2016;13(3):79-80
pages 79-80 views

The effectiveness of vaccinal prevention of community-acquired pneumonia in organized groups of adults under extreme conditions

Rakhmanov R.S., Potekhina N.N., Mikhanoshina N.V., Basalyga V.N., Sgibnev D.V.
Russian Journal of Allergy. 2016;13(3):81-82
pages 81-82 views

Cytokine balance in pathogenesis of latent rhinosinusitis

Stagnieva I.V., Simbirtsev A.S.
Russian Journal of Allergy. 2016;13(3):82-83
pages 82-83 views

Determining severity of rhinosinusitis on cytokine balance

Stagnieva I.V., Gukasyan E.L.
Russian Journal of Allergy. 2016;13(3):83-84
pages 83-84 views

XXXV EAACI congress, 2016, Vienna, Austria

Latisheva E.A., Khaitov M.R.
Russian Journal of Allergy. 2016;13(3):85-87
pages 85-87 views

Congresses, Conferences

- -.
Russian Journal of Allergy. 2016;13(3):91-91
pages 91-91 views

AD Memorandum. Igor Georgievich Sidorovitch (19.07.1939-23.04.2016)

- -.
Russian Journal of Allergy. 2016;13(3):92-92
pages 92-92 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies